41. Advanced Search April 1, 1999 AFP multiple myeloma Recognition and Management. TABLE 1 Red Flagsfor Potential Diagnosis of multiple myeloma in Patients with Back Pain. http://www.aafp.org/afp/990401ap/1885.html

Advanced Search Multiple Myeloma: Recognition and Management ENITZA D. GEORGE, M.D., and RICHARD SADOVSKY, M.D., M.S. State University of New York Health Science Center Brooklyn, New York A patient information handout on multiple myeloma, written by the authors of this article, is provided on page 1893. M ultiple myeloma is a malignant proliferation of plasma cells that involves more than 10 percent of the bone marrow. It is a prototype primary malignancy of the bone associated with malignant plasma cells that secrete monoclonal immunoglobulins into the serum, the urine or both. Agricultural workers, farmers, sheet metal workers and persons employed in the nuclear industry or who are exposed to wood dust are at increased risk of developing multiple myeloma. The family physician is often the first to identify multiple myeloma. The expertise of an oncologist is then enrolled. Other specialists join the team as needed to address specific concerns or complications. As with other malignancies, the family physician assists the patient and the family in understanding the disease and the treatment-related side effects, and in improving the patient's overall quality of life. In 1850, MacIntyre published the first complete clinical and pathologic narration of "a case of mollities and fragilitas ossium accompanied with urine strongly charged with animal matter." The term "multiple myeloma" was first used to describe the presence of multiple tumors originating in the bone.

42. Advanced Search An article on this topic is available in this issue of AFP. What ismultiple myeloma? How Is It Treated? What is multiple myeloma? http://www.aafp.org/afp/990401ap/990401f.html

Advanced Search Please note: This information was as current as we could make it on the date given above. But medical information is always changing, and some information given here may be out of date. For regularly updated information on a variety of health topics, please visit familydoctor.org , the AAFP patient education Web site. An article on this topic is available in this issue of AFP What is Multiple Myeloma? How Is It Treated? What is multiple myeloma? Multiple myeloma (say: mull-tip-ul my-el-oh-ma) is a kind of cancer. It's caused when cells in the bone, called "plasma cells," grow too much. When this happens, the plasma cells kill the bone around them. The plasma cells also make too much of something called "immunoglobulins." The immunoglobulins cause problems in the blood. What causes myeloma? We don't know what causes myeloma. This cancer usually happens in people older than 55 years of age. Slightly more men than women get it. It doesn't usually run in families. Myeloma is more common in blacks than in whites. Fertilizers and insecticides might cause myeloma. This may be why myeloma is more common in farmers. How does my doctor know I have myeloma?

43. Multiple Myeloma multiple myeloma. most common primary malignant neoplasm of bone;5070y; MF 21. symptoms vague bone pain of progressive severity http://chorus.rad.mcw.edu/doc/01056.html

CHORUS Collaborative Hypertext of Radiology Musculoskeletal system Feedback Search multiple myeloma most common primary malignant neoplasm of bone 50-70y; M:F 2:1 symptoms: vague bone pain of progressive severity, fever, anemic sxs complications: pathologic fractures solitary plasmacytoma: solitary osseous focus of MM (uncommon) x-ray findings: loss of bone density - from diffuse marrow involvement "punched out" lesions - esp. skull, long bones diffuse bone destruction - esp. pelvis, sacrum invasion of soft tissues - often paraspinal, extrapleural mass osteosclerosis - very rare metastatic calcifications - particularly kidneys, occ. lungs NB: does not involve pedicles of spine Brian Funaki, MD - 6 February 1995 Last updated 14 March 2001 Medical College of Wisconsin

44. CancerHelp UK multiple myeloma. http://www.cancerhelp.org.uk/help/default.asp?page=4746

45. CancerHelp UK Treating multiple myeloma. This section tells you about the treatment for multiplemyeloma. You can choose from the following menu The stages Which treatment? http://www.cancerhelp.org.uk/help/default.asp?page=4749

46. What You Need To Know About Multiple Myeloma Welcome to CancerLinksUSA. Booklet What You Need to Know about multiple myeloma,National Cancer Institute Logo, Introduction What Is multiple myeloma? http://www.thecancer.info/myeloma/wynk/

Cancer Information Search Ends Here Click Here Top Feature Top 10 Links Associations Cancer Centers Research ... Glossary For Professionals Main Page Journal Club Meetings Tools About Us Book Store Contact Us Message Board Other Links Newsgroups Welcome to CancerLinksUSA Booklet: What You Need to Know about Multiple Myeloma Content of the Booklet: Introduction What Is Multiple Myeloma? Normal Cells Cancer ... Glossary For more on Multiple Myeloma: For more on CancerLinksUSA: Multiple Myeloma Home Page Back to Home Page Please Visit Our Sponsors Site Index Site Map Contact Us Guest Book ... About CancerLinksUSA By accessing and using this page you agree to the Terms of Service. Info for Advertisers

47. Cancer Research UK: Multiple Myeloma multiple myeloma Summary. multiple myeloma is the 12th most common cancerin men, and the 13th most common cancer in women in the UK. http://www.cancerresearchuk.org/aboutcancer/specificcancers/23554

About us About cancer Press office Get involved ... Contact our information nurses Multiple myeloma If you or a friend or relative have been diagnosed with cancer, you will find much more detailed information on our patient information site, CancerHelp UK Summary Multiple myeloma is the 12th most common cancer in men, and the 13th most common cancer in women in the UK. Each year, there are over 3,200 new cases. Myeloma develops from cells within the bone marrow called plasma cells. Plasma cells produce proteins called antibodies, which help to fight infection. In myeloma, a single plasma cell develops faults and multiplies out of control. This makes the immune system much less effective at fighting infection. Myeloma cells produce excessive amounts of a single type of antibody, which is known as paraprotein, or monoclonal spike. Myeloma usually develops at a number of different sites within the body. This cancer is therefore called multiple myeloma. The most common sites for multiple myeloma are the pelvis, spine, rib cage, skull, shoulders and hips. Risk Factors Age Multiple myeloma is more common from the age of 50 onwards.

48. Multiple Myeloma, The Cancer Information Network Introduction multiple myeloma is a malignant disease occurs in the bonemarrow. In The Spotlight I am diagnosed with multiple myeloma. http://www.ontumor.com/myeloma/index.asp

Thank You For Visiting Our Site! Home Support Top 10 Message Board ... Ask An Oncologist First Steps After Diagnosis of Cancer Top 10 Cancer Sites, Treatment Centers, and Cancer Books for Newly Diagnosed Patients. Understanding Prognosis and Cancer Statistics - answers the most important question, "What is my prognosis?" Support Groups for Cancer Patients Find a Cancer Treatment Center ... Pediatric Cancers Welcome to The Cancer Information Network Introduction Multiple Myeloma is a malignant disease occurs in the bone marrow. This year, about 14,6000 people will be diagnosed with this malignancy. The diagnosis of multiple myeloma brings with them many questions and a need for clear, understandable answers... In The Spotlight: " I am diagnosed with multiple myeloma. Where can I obtain answers to my questions?" - Get answers of your questions of multiple myeloma from a board-certified oncologist. Questions about cancer or its treatment?

49. Multiple Myeloma multiple myeloma. Roughly infections. In case of multiple myeloma, the abnormalplasma cells produce abnormal and dysfunctional immune globulins. http://www.tirgan.com/myeloma.htm

Home Services Contact Links ... Chemotherapy Drugs Multiple Myeloma Roughly 13,000 Americans develop this illness every year. It is more frequent in men than in women. It is more commonly seen after age of 60. This disease is due to overproduction of Plasma cells from the bone marrow . Under normal circumstances, these cells are in charge of producing immune globulins, the immune proteins that our body needs to fight infections. In case of Multiple Myeloma, the abnormal plasma cells produce abnormal and dysfunctional immune globulins. One that is used as an indicator of the disease is known as Beta 2 microglobulin . This disease is basically diagnosed by detecting these abnormal immune globulins in the blood, or alternatively, by observing the abnormal plasma cells in the bone marrow. Causes: The cause of this illness is unknown. Signs and Symptoms Patients may not show any signs for quite sometime. This illness can present itself in many different fashions. 20% of patients are diagnosed incidentally, and during work up on another problem. As the disease progresses, it can cause any of the following problems: Bone pain High calcium levels Kidney failure Anemia ... Hyperviscosity Syndrome Frequent infections Fever Weight loss Diagnosis The diagnosis is established by certain blood tests and also taking a biopsy of the bone marrow.

50. ECOG- Frequently Asked Questions About The Multiple Myeloma Study (E1A00) ECOG Frequently Asked Questions about the multiple myeloma Study (E1A00) -Followthe link below to view the handout answering frequently asked questions about http://www.ecog.org/general/E1A00info.html

ECOG Introduction to ECOG Clinical Trials What is a clinical trial? Why participate? Does insurance cover costs? What if I change my mind? ... Cancer in Siblings Study Trial Monitoring ECOG Data Monitoring Committee Guidelines ECOG Institutions Institutions by state Alphabetical listing Publications Publications bibliography Announcements Job Openings Future ECOG Meeting Dates Researcher Advocate Partners Young Investigator Awards ... NCI-VA Initiative Scales and Criteria ECOG Performance Status Common Toxicity Criteria Cancer Information Breast Cancer Video Cancer Survivor Publications Other Cancer Sites ECOG Institutions' Sites Other Cooperative Groups Advocates/Support Groups ECOG HOME PAGE ... INFORMATION (password required) GLOSSARY SEARCH CONTACT INFORMATION ECOG- Frequently Asked Questions about the Multiple Myeloma Study (E1A00) Follow the links below to view an announcement and a handout answering frequently asked questions about the ECOG Multiple Myeloma Study (E1A00). This is a "randomized Phase III trial of Thalidomide (NSC#66847) plus Dexamethasone versus Dexamethasone in newly diagnosed Multiple Myeloma". Multiple Myeloma Clinical Trial Announcement Frequently Asked Questions about the Multiple Myeloma Study The document is in Adobe Acrobat format. If you do not already have Adobe Acrobat Reader running on your computer you can

51. Anomalies MMUL NA multiple myeloma. Clinics and Pathology. Disease, multiple myeloma(MM) is a malignant plasma cell proliferation. Phenotype http://www.infobiogen.fr/services/chromcancer/Anomalies/MMUL.html

Atlas of Genetics and Cytogenetics in Oncology and Haematology Home Genes Leukemias Solid Tumours ... NA Multiple myeloma Clinics and Pathology Disease multiple myeloma (MM) is a malignant plasma cell proliferation Phenotype / cell stem origin phenotype of mature terminally differenciated B-cell, but also with CD56 expression, which is not found in normal plasma cells; CD38+ CD40+ Epidemiology multiple myeloma's annual incidence: 30/10 ; i.e. around 1% of malignancies in adults and 10ù of haematologic malignancies; mean age: 62 yrs Clinics patients may be asymptomatic at the time of diagnosis; bone pain; susceptibility to infections; renal failure; neurologic dysfunctions Pathology MM staging: stage I: tumour cell mass 10 g/dl; serum calcium ¾ 120 mg/l; no bone lesion; low monoclonal Ig rate (IgG < 50 g/l, IgA < 30 g/l, BJ urine 1.2 X 1012/m2; Hb 120 mg/l and/or advanced lytic bone lesions and/or high monoclonal Ig rate (IgG > 70 g/l, IgA > 50 g/l, BJ urine > 12 g/day) Treatment none before onset of symptoms; chemotherapy or BMT afterwards Prognosis evolution: multiple myeloma can evolve towards plasma cell leukemia , where plasma cell count is greater than 2000/ mm3; survival is highly variable (median is around 3 yrs); prognosis is according to the staging and other parameters (such as age, serum albumin, b2 microglobulin, C-reactive protein, and plasma cell labeling index); the karyotype is emerging as an important prognostic factor: median survival in case of a normal karyotype could be 4 yrs vs 1 yr in case of -13/del(13q) and/or 11q rearrangements (the chromosome anomalies with the worst prognostic impact)

52. Multiple Myeloma: BC Cancer Agency Types of Cancer multiple myeloma Print Wizard Print this Page GeneralInformation / Anatomy / Function / Statistics Myelomas are http://www.bccancer.bc.ca/PPI/TypesofCancer/MultipleMyeloma/

Agency Links: Home Contact Us Legal Privacy ... Types of Cancer Multiple Myeloma Types of Cancer Multiple Myeloma Diagnosis Etiology Prevention Symptoms ... Vulva Types of Cancer - Multiple Myeloma Print Wizard Print this Page General Information / Anatomy / Function / Statistics Other common problems include low blood counts, anemia, kidney problems and repeated infections Male Female Revised April 2000 Print Wizard Print this Page The BC Cancer Agency is a part of the Provincial Health Services Authority If you notice a problem with this page, please report it via the Bug Report Form . Thank you. Unofficial document if printed . Please refer to the following web address for up-to-date information:

53. Multiple Myeloma Treatment And Research - City Of Hope Providing research and treatment centers for multiple myeloma and otherlifethreatening diseases, including diabetes and HIV/AIDS. http://www.cityofhope.org/multiple_myeloma/

A Leader In Multiple Myeloma Treatment And Research City of Hope Cancer Center is one of the world's leading research and treatment centers for multiple myeloma, other cancers, and life-threatening diseases including diabetes and HIV/AIDS. A pioneer in the field of bone marrow transplantation, City of Hope is one of just 40 NCI-designated Comprehensive Cancer Centers. Here, over 2,800 physicians, researchers, and health care professionals join forces to provide novel treatments and clinical trials, state-of-the-art care, and compassion for our patients. Home to the Beckman Research Institute, research conducted at City of Hope has lead to remarkable discoveries that have helped millions of people worldwide. Our Mission: City of Hope, inspired and supported by a philanthropic volunteer movement, is dedicated to the prevention, treatment and cure of cancer and other life-threatening diseases through innovative research and patient care.

54. Joint Program In Nuclear Medicine Bone Scintigraphy in multiple myeloma. David A. Bader MD. All of the aboveimaging findings were consistent with the diagnosis of multiple myeloma. http://www.med.harvard.edu/JPNM/TF94_95/Jan17/WriteUpJan17.html

Bone Scintigraphy in Multiple Myeloma David A. Bader MD J. Stevan Nagel MD January 17, 1995 Case Presentation: A 48 year old male with no significant past medical history fell onto his right shoulder at home. A radiograph was obtained and revealed a pathologic fracture of the proximal humerus through a lytic lesion. A bone scan was requested to evaluate for fibrous dysplasia. Findings: Bone scan (63k bytes) revealed no significant activity corresponding to the known fracture site. There were several foci of anterior rib activity and an additional focus of mild to moderate increased activity in the left distal medial femur. Plain films of the ribs (95k bytes) and left femur (41k bytes) were obtained for comparison at the time of the nuclear medicine study and revealed a diffuse lytic process involving essentially all of the visible bones. The mild increased activity in the left femur ( arrow , 63k bytes) on bone scintigraphy activity was noted to correspond to periosteal reaction ( arrow , 41k bytes) at a site of pathologic fracture. All of the above imaging findings were consistent with the diagnosis of multiple myeloma. Imaging Technique: A whole body bone scan was performed following the administration of 25 mCi of Tc-99m MDP utilizing 3 hour delayed regional planar images on a Siemens body scan (dual head) with a low energy high resolution collimator.

55. Virtual Hospital: ElectricPE: The Diagnosis Of Pulmonary Embolism: Multiple Myel multiple myeloma. This case is a 51 year old male with known multiplemyeloma who returned for his third course of chemotherapy. http://www.vh.org/adult/provider/radiology/ElectricPE/Patients/Case13.html

For Providers ElectricPE: The Diagnosis of Pulmonary Embolism: Case Study 13 Multiple Myeloma Jeffrey R. Galvin, M.D. and James J. Choi, B.S. Peer Review Status: Externally Peer Reviewed by the AMA This case is a 51 year old male with known multiple myeloma who returned for his third course of chemotherapy. During the admissions history and physical the patient reported a one week history of left posterior pleuritic chest pain that felt better when he rubbed the area with his hand. He had dyspnea on exertion but not at rest. He denied cough, fever, or hemoptysis. He also reported an episode of left lower extremity pain that began 3 weeks ago. The pain has decreased but the swelling has persisted. His arterial blood gases on admission were PH 7.45 Pco2 33 Po2 64 He had a low grade temperature 37.9 The chest x-ray showed a pleural based density in the left costophrenic angle and a linear density in the posterior aspect of the left lower lobe. The perfusion scan showed an area of decreased perfusion in the posterior aspect of the left lower lobe that matched the area of infiltrate in the left lower lobe on the chest radiograph. The ventilation scan showed decreased ventilation in the posterior aspect of the left lower lobe.

56. Cancer.gov - Dictionary M. M proteins Antibodies or parts of antibodies found in unusually largeamounts in the blood or urine of people with multiple myeloma. http://www.nci.nih.gov/dictionary/db_alpha.aspx?expand=M

57. Multiple Myeloma multiple myeloma. The incidence of myeloma the disease. . Plasmacytoma,multiple myeloma Bone scans of multiple myeloma. multiple myeloma http://www.cp-tel.net/pamnorth/bone.htm

Multiple Myeloma The incidence of myeloma is 3-4/100,000 in the U.S. This translates into approximately 13,500 new cases of myeloma in the U.S. each year. Myeloma is more common in blacks than whites. The incidence varies from country to country around the world from a low of 1/100,000 in China to approximately 4/100,000 in most Western industrialized countries. The male/female ratio is 3:2. The incidence rises with age. Better diagnostic techniques and the higher average age of the general population may explain the rising incidence over the last decades. However, a trend toward more frequent myeloma in patients under age 55 implies important environmental causative factors in the past 3-4 decades. Source: International Myeloma Foundation The International Myeloma Foundation "The IMF is a non-profit organization dedicated to improving the quality of life for multiple myeloma patients while working towards prevention and a cure." Understanding Myeloma "This booklet has been written to help you understand more about myeloma. We hope it answers some of the questions you may have about its diagnosis and treatment, and addresses some of the feelings which are a large part of anyone's reaction to a cancer diagnosis." Myeloma Information and links from OncoLink.

58. Multiple Myeloma - Genetics Overview of the Molecular Biology of multiple myeloma. Ludwig H, et al. Multiple Information.Cytogenetics of multiple myeloma. PerezSimon JA, et al. http://www.cancerindex.org/geneweb/X1301.htm

Cancer Genetics Web www.cancer genetics.org Multiple Myeloma Mutated Genes and Abnormal Protein Expression Recurrent Chromosome Abnormalities Overview of the Molecular Biology of Multiple Myeloma Cytogenetics of Multiple Myeloma Loss of Chromosome 13 in Multiple Myeloma t(11;14)(q13;q32) in Multiple myeloma Familial Clustering in Multiple Myeloma Multiple Myeloma: Clinical and Epidemiological Resources Mutated Genes and Abnormal Protein Expression Gene Location Topics SDC1 Expression in Multiple Myeloma LTA ( TNFB , LT ) LTA Polymorphisms and Risk of MGUS and Myeloma TNF ( TNFA , TNFSF2 , DIF ) TNF Polymorphisms and Risk of MGUS and Myeloma ( MUM1 , LSIRF ) t(6;14)(p25;q32) in Multiple Myeloma IL6 Expression in Multiple Myeloma HGF ( HPTA ) HGF Expression in Multiple Myeloma ( D11S287E , Cyclin D , PRAD1 ) CCND1 Amplification and Overexpression in Multiple Myeloma B2M and Multiple Myeloma CD19 Expression in Multiple Myeloma Recurrent Chromosome Abnormalities t(6;14)(p25;q32) in Multiple Myeloma Loss of Chromosome 13 in Multiple Myeloma t(11;14)(q13;q32) in Multiple myeloma

59. Latest Multiple Myeloma (Plasma Cells) Treatments multiple myeloma. (PLASMA CELLS). What are Plasma Cells ? When it is in multipleareas, it is called multiple myeloma . How common is Plasmacytoma? http://www.cancergroup.com/em23.html

M ULTIPLE M YELOMA (P LASMA C ELLS What are "Plasma Cells"? Plasma cells are "B" lymphocytes in their final stage of development, when they are actually producing antibodies to fight "germs" like bacteria, viruses, fungi or protozoan parasites. They are an integral part of the immune system . There are basi-cally two types of immunity, called "cellular" and "humoral" immunity. Lymphocytes are white blood cell (about 30% of adult's while blood cells) that are actively involved in both types of immunity. "Cellular" immunity means that the white blood cells directly kill foreign invading germs, such as by enveloping and digesting them, while the "humoral" type means that the invaders are coated by antibodies and then gradually enveloped and digested by other white blood cells. The invading germs have markers on their cell surfaces, called "antigens" which tell the immune system that they are foreign to the body. The two common types of lymphocytes are "T" and "B" cells. "T" cells specialize in recognizing germs and activating the immune system, while "B" cells produce specific antibodies against the antigens that the "T" cells have recognized. The "B" cells go through a number of stages of development, and the final one is that they are specifically programmed to become antibody producing factories. The antibodies produced are specific to attack a particular kind of germ or foreign tissue. At this final stage of development, they are called

60. AltaRex.com SEC Filings. ovarian cancer trials. ovarian cancer trial results. multiple myelomatrials. antibodies in development. technology platform. intellectual property. http://www.altarex.com/html/Multiple_Myeloma .shtml

17-patient trial Study BRV-MCI-01 COMPLETED for Primary Analysis This is a Phase I study of BrevaRex® in patients with metastatic cancers that express the MUC1 antigen. The study focused on the safety and immunology of three different doses. Primary endpoints: Safety, Immunology Final Phase I results have been reported (December 2000) stock quote fact sheet .pdf stock chart analyst coverage ... request for information

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 111    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20